ClinicalTrials.gg
CompletedNCT01432444ARRIVE USUpdated May 7, 2015Results posted

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

A Phase 3 interventional study of Aripiprazole (Abilify®) IM Depot Injection in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 124 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-05-07.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
19th of 125
493 · median 130
Started
2011
with 3 others
Phase 3
34 of 126
1 open now
Registered
69th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 19th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2011, is one of 34 in phase 3, and was the 69th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.

Read the detailed description

Nonadherence to antipsychotic medications remains a frequent cause of relapse among patients with schizophrenia, increasing hospitalization rates, hospitalization days, and hospitalization costs. Among hospitalized adults, schizophrenia is the fourth most commonly diagnosed illness and has the seventh longest mean duration of hospital stay in the US. Frequent relapses and hospitalization can affect quality of life in these patients. Long-acting injections (intramuscular depot) antipsychotic medication is a means to treatment adherence and increased quality of life for patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to provide written . If the IRB requires consent by a legally acceptable representative in addition to the subject, all required consents must be obtained prior to any protocol-required procedure.
  • Male and female subjects 18 to 65 years of age, inclusive.
  • Current diagnosis of schizophrenia as defined by criteria and a history of the illness for at least 1 year (12 months).
  • Subjects who in the investigator's judgment would benefit from extended treatment with a long-acting injectable formulation.
  • Subjects who have at least 1 inpatient psychiatric hospitalization in the 4 years (48 months) prior to screening, but have been managed as outpatients for the 4 weeks prior entering the study.
  • Subjects must have been on oral antipsychotic treatment for the full 7 months prior to the screening phase.
  • Subjects who have shown response to previous antipsychotic treatment.
  • Subjects who understand the nature of the trial and are able to follow the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated), or have been incarcerated in the past 7 months for any reason must not be enrolled into this trial.
  • Subjects who may require potent CYP2D6 or inhibitors or CYP3A4 inducers during the trial.
  • Any subject who requires or may need any other antipsychotic medications during the course of the trial, other than allowed rescue medication.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
  • Subjects with a history of to antipsychotic agents.
  • Subjects deemed intolerant of receiving injectable treatment.
  • Subjects who have received electroconvulsive therapy within the last 7 months prior to screening.
  • Subjects with a history of neuroleptic malignant syndrome or tardive dyskinesia as assessed by the investigator.
  • Subjects with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects requiring hospitalization for any psychiatric reason during the 4 weeks prior to signing the ICF or during the screening period.
  • Subjects without at least 1 inpatient psychiatric hospitalization in the last 4 years (48 months) prior to screening.
  • Subjects who have met DSM-IV-TR criteria for any significant substance use disorder within 3 months prior to screening.
  • Subjects who are considered treatment-resistant to antipsychotic medication other than clozapine.
  • Treatment with long-acting injectable antipsychotics in which the last dose was within 7 months prior to screening.
  • Subjects who have not been treated with oral antipsychotics for 7 months prior to screening.
  • Subjects who have a significant risk of committing suicide
  • Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial.
  • Females who are pregnant or lactating, sexually active males and females who will not commit to utilizing during the trial and for up to 180 days following the trial.
  • Abnormal laboratory or physical examination results indicating a condition which may interfere with the results of the study or pose a safety risk to the subject.
  • Subjects who have previously enrolled in an aripiprazole IM depot clinical study, except for subjects entering this trial from the Canadian 31-11-284 trial.
  • Subjects who have participated in any clinical trial with an agent within the past 30 days.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    OPC-14597

    Aripiprazole IM depot injection 300 mg or 400 mg.

    Drug: Aripiprazole (Abilify®) IM Depot Injection

Interventions

  • 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg. Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013.

    Also known as: ABILIFY®

06

What researchers measure

Primary outcomes

  1. Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).

    The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥ inpatient psychiatric hospitalizations) between the retrospective period months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot. Open-label Aripiprazole IM Depot Treatment Phase 3-month Completer sample comprised of all participants who entered open-label aripiprazole IM depot treatment Phase and completed at least 3 months of treatment. This sample was used for the primary endpoint analysis (N=336).

    Time frame: Retrospective period Months 4-6; Prospective period Months 4-6

Secondary outcomes

  1. Change From Baseline in PANSS (Positive and Negative Syndrome Scale) Total Score.

    The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The PANSS total score ranges from 30 to 210.

    Time frame: Baseline to Week 24

  2. Change From Baseline in PANSS Positive Subscale Score.

    The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity suspiciousness/ persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Week 24

  3. Change From Baseline in PANSS Negative Subscale Score.

    The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 negative symptom constructs are blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline to Week 24

  4. Change From Baseline in Clinical Global Impression-Severity Score (CGI-S).

    The severity of illness for each participant were rated using the CGI-S scale. To assess CGI-S, study physician were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.

    Time frame: Baseline to Week 24

  5. Mean Clinical Global Impression-Improvement Score (CGI-I) by Week.

    The efficacy of trial medication was rated for each participant using the CGI-I scale. The study physician would rate the participants total improvement whether or not it was entirely due to drug treatment. All responses were compared to the participants condition at Baseline of the appropriate phase. The CGI-I during Phase B were assessed relative to the participants condition at the Phase B Baseline visit. Response choices included: 0 = not assessed; 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.

    Time frame: Week 4, 12 and 24

07

Results

Posted Mar 27, 2015

Participant flow

This study assessed hospitalization rates in adults with schizophrenia treated prospectively for 6 months with aripiprazole intramuscular depot compared with 6 month retrospective treatment with oral antipsychotics. The study comprised 3 phases: Tolerability/Cross-titration (Phase A), Open-label Aripiprazole (Phase B), Extension (Phase C).

Tolerability/Cross-titration Phase
Participant flow — Tolerability/Cross-titration Phase
MilestoneTolerability/Cross-titration Phase (Phase A)Open-label Aripiprazole IM Depot Treatment Phase (Phase B)Extension Phase (Phase C)
Started32500
Completed26500
Not completed6000
Withdrew: Lost to follow-up1000
Withdrew: Adverse event1600
Withdrew: Met withdrawal criteria500
Withdrew: Physician decision800
Withdrew: Withdrawal by subject1500
Withdrew: Protocol deviation100
Withdrew: Lack of efficacy500
Treatment Phase
Participant flow — Treatment Phase
MilestoneTolerability/Cross-titration Phase (Phase A)Open-label Aripiprazole IM Depot Treatment Phase (Phase B)Extension Phase (Phase C)
Started04330
Completed02930
Not completed01400
Withdrew: Lost to follow-up0330
Withdrew: Adverse event0370
Withdrew: Met withdrawal criteria0110
Withdrew: Physician decision050
Withdrew: Withdrawal by subject0410
Withdrew: Protocol deviation030
Withdrew: Lack of efficacy0100
Extension Phase
Participant flow — Extension Phase
MilestoneTolerability/Cross-titration Phase (Phase A)Open-label Aripiprazole IM Depot Treatment Phase (Phase B)Extension Phase (Phase C)
Started00192
Completed000
Not completed00192
Withdrew: Lost to follow-up0017
Withdrew: Adverse event0010
Withdrew: Sponsor discontinued trial007
Withdrew: Met withdrawal criteria00144
Withdrew: Physician decision001
Withdrew: Withdrawal by subject0013

Outcome measures

PrimaryNumber of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).

The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥ inpatient psychiatric hospitalizations) between the retrospective period months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot. Open-label Aripiprazole IM Depot Treatment Phase 3-month Completer sample comprised of all participants who entered open-label aripiprazole IM depot treatment Phase and completed at least 3 months of treatment. This sample was used for the primary endpoint analysis (N=336).

Time frame:
Retrospective period Months 4-6; Prospective period Months 4-6
Reported as:
Number · participants
Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).
participantsOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)
Retrospective period91 ± 0.6
Prospective period9 ± 0.2
Statistical analysis
  • Open-label Aripiprazole IM Depot Treatment Phase (Phase B) · McNemar · p = <.0001 (P-value was derived from Exact McNemar test.)
SecondaryChange From Baseline in PANSS (Positive and Negative Syndrome Scale) Total Score.

The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The PANSS total score ranges from 30 to 210.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS (Positive and Negative Syndrome Scale) Total Score.
Units on a scaleOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)
Week 4 (N= 390)-7.9 ± 14.0
Week 12 (N= 410)-8.4 ± 15.6
Week 24 (N= 410)-8.4 ± 17.7
Statistical analysis
  • Open-label Aripiprazole IM Depot Treatment Phase (Phase B) · t-test · p = <.0001 (Derived from T-test of Mean=0.)Mean duration was derived as the cumulative duration divided by the number of inpatient non-psychiatric hospitalization.
SecondaryChange From Baseline in PANSS Positive Subscale Score.

The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity suspiciousness/ persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Positive Subscale Score.
Units on a scaleOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)
Week 4 (N= 390)-2.7 ± 4.4
Week 12 (N= 410)-2.9 ± 4.9
Week 24 (N= 410)-3.0 ± 5.4
Statistical analysis
  • Open-label Aripiprazole IM Depot Treatment Phase (Phase B) · t-test, 2 sided · p = <.0001 (Derived from T-test of Mean=0.)Mean duration was derived as the cumulative duration divided by the number of inpatient non-psychiatric hospitalization.
SecondaryChange From Baseline in PANSS Negative Subscale Score.

The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 negative symptom constructs are blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Negative Subscale Score.
Units on a scaleOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)
Week 4-1.7 ± 4.6
Week 12-1.6 ± 5.1
Week 24-1.6 ± 5.8
Statistical analysis
  • Open-label Aripiprazole IM Depot Treatment Phase (Phase B) · t-test, 2 sided · p = <.0001 (Derived from T-test of Mean=0.)Mean duration was derived as the cumulative duration divided by the number of inpatient non-psychiatric hospitalization.
SecondaryChange From Baseline in Clinical Global Impression-Severity Score (CGI-S).

The severity of illness for each participant were rated using the CGI-S scale. To assess CGI-S, study physician were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression-Severity Score (CGI-S).
Units on a scaleOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)
Week 4 (N= 391)-0.3 ± 0.8
Week 12 (N= 410)-0.4 ± 0.9
Week 24 (N= 410)-0.5 ± 1.0
Statistical analysis
  • Open-label Aripiprazole IM Depot Treatment Phase (Phase B) · t-test · p = <.0001 (Derived from t-test of mean=0.)
SecondaryMean Clinical Global Impression-Improvement Score (CGI-I) by Week.

The efficacy of trial medication was rated for each participant using the CGI-I scale. The study physician would rate the participants total improvement whether or not it was entirely due to drug treatment. All responses were compared to the participants condition at Baseline of the appropriate phase. The CGI-I during Phase B were assessed relative to the participants condition at the Phase B Baseline visit. Response choices included: 0 = not assessed; 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.

Time frame:
Week 4, 12 and 24
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement Score (CGI-I) by Week.
Units on a scaleOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)
Week 4 (N= 283)2.9 ± 0.9
Week 12 (N= 293)2.7 ± 1.0
Week 24 (N= 293)2.5 ± 1.0

Adverse events

Collected over Adverse events were monitored from ICF signed until Follow-up 30 (± 3) days after last visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Aripiprazole IM Depot Treatment Phase (Phase B)—61/431 (14.2%)60/431 (13.9%)
Extension Phase (Phase C)—19/192 (9.9%)24/192 (12.5%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)Extension Phase (Phase C)
Schizophrenia, paranoid typePsychiatric disorders14/4313/192
SchizophreniaPsychiatric disorders11/4316/192
Psychotic disorderPsychiatric disorders8/4313/192
Suicidal ideationPsychiatric disorders6/4311/192
ConvulsionNervous system disorders4/4311/192
Suicide attemptPsychiatric disorders3/4311/192
Angina pectorisCardiac disorders0/4311/192
Cardio-respiratory arrestCardiac disorders0/4311/192
Hepatitis acuteHepatobiliary disorders0/4311/192
Type 2 diabetis mellitusMetabolism and nutrition disorders1/4311/192
Most frequent other events
Most frequent other events
EventOpen-label Aripiprazole IM Depot Treatment Phase (Phase B)Extension Phase (Phase C)
InsomniaPsychiatric disorders29/4316/192
AkathisiaNervous system disorders27/4319/192
Weight increasedInvestigations10/43111/192

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Open-label Aripiprazole IM Depot Treatment Phase (Phase B)
Mean42.1 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Aripiprazole IM Depot Treatment Phase (Phase B)
Female132
Male301
08

Study locations

124 sites
  • Dothan, Alabama 36305, United States
  • Tucson, Arizona 85719, United States
  • Fayetteville, Arkansas 72703, United States
  • Little Rock, Arkansas 72201, United States
  • Anaheim, California 92801, United States
  • Anaheim, California 92804, United States
  • Bellflower, California 90706, United States
  • Carson, California 90746, United States
  • Costa Mesa, California 92626, United States
  • Downey, California 90241, United States
  • Escondido, California 92025, United States
  • Garden Grove, California 92845, United States
  • Glendale, California 91204, United States
  • Glendale, California 91206, United States
  • Los Angeles, California, United States
  • National City, California 91950, United States
  • Norwalk, California 60950, United States
  • Oakland, California 94612, United States
  • Oceanside, California 92056, United States
  • Orange, California, United States
  • Palo Alto, California 94304, United States
  • Paramount, California 92626, United States
  • Pasadena, California 91106-2500, United States
  • Riverside, California 92506, United States
  • San Diego, California 92108, United States
  • San Diego, California 92117, United States
  • San Diego, California 92121, United States
  • San Francisco, California 94104, United States
  • Santa Ana, California 92705, United States
  • Torrance, California 90502, United States
  • Middletown, Connecticut 06457, United States
  • New Brittain, Connecticut 06050, United States
  • Norwalk, Connecticut 06851, United States
  • Boynton Beach, Florida 33435, United States
  • Coral Gables, Florida 33134, United States
  • Doral, Florida 33172, United States
  • Hialeah, Florida 33014, United States
  • Jacksonville Beach, Florida 32250, United States
  • Miami, Florida 33122, United States
  • Miami, Florida 33125, United States
  • Miami, Florida 33135, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33144, United States
  • Miami, Florida 33155, United States
  • Oakland Park, Florida 33334, United States
  • Orange City, Florida 32763, United States
  • Orlando, Florida 32803, United States
  • Plantation, Florida 33317, United States
  • South Miami, Florida 33143, United States
  • St. Augustine, Florida 32086, United States
  • St. Petersburg, Florida 33716, United States
  • Tampa, Florida 33559, United States
  • Tampa, Florida 33613, United States
  • Atlanta, Georgia 30301, United States
  • Decatur, Georgia 30030, United States
  • Marietta, Georgia 30062, United States
  • Chicago, Illinois 60611-4296, United States
  • Joliet, Illinois 60435, United States
  • Naperville, Illinois 60563, United States
  • South Bend, Indiana 46617, United States
  • Topeka, Kansas 66606, United States
  • Witchita, Kansas 67207, United States
  • Boston, Massachusetts 02114, United States
  • Brockton, Massachusetts 02301, United States
  • Newton, Massachusetts 02458, United States
  • Bloomfield Hills, Michigan 48302, United States
  • Grand Rapids, Michigan 49503, United States
  • Paw Paw, Michigan 49079, United States
  • Minneapolis, Minnesota 55454, United States
  • Creve Coeur, Missouri 63141, United States
  • Kansas City, Missouri 64108, United States
  • Kansas City, Missouri 64114, United States
  • St. Charles, Missouri 63301, United States
  • St. Louis, Missouri 63128, United States
  • Lincoln, Nebraska 68526, United States
  • North Platte, Nebraska 69101, United States
  • Sparks, Nevada 89434, United States
  • Nashua, New Hampshire 03060, United States
  • Albuquerque, New Mexico 87106, United States
  • Amherst, New York 14226, United States
  • Brooklyn, New York 11203, United States
  • Brooklyn, New York 11206, United States
  • Brooklyn, New York 11241, United States
  • Buffalo, New York 14215, United States
  • New York, New York 10027, United States
  • New York, New York 10065, United States
  • New York, New York 10128, United States
  • Rochester, New York 14615, United States
  • Rochester, New York 14618, United States
  • Syracuse, New York 13202, United States
  • Wards Island, New York 10035, United States
  • Charlotte, North Carolina 28204, United States
  • Durham, North Carolina 27704, United States
  • Canton, Ohio 44718, United States
  • Centennial, Ohio 80112, United States
  • Garfield Heights, Ohio 44125, United States
  • Mason, Ohio 45040, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Oklahoma City, Oklahoma, United States
  • McMurray, Pennsylvania 15317, United States

Showing the first 100 of 124 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Peters-Strickland T, Zhao C, Perry PP, Eramo A, Salzman PM, McQuade RD, Johnson BR, Sanchez R. Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics. CNS Spectr. 2016 Dec;21(6):460-465. doi: 10.1017/S1092852916000365. Epub 2016 Aug 17. PubMed 27531181 ↗
  • Kane JM, Zhao C, Johnson BR, Baker RA, Eramo A, McQuade RD, Duca AR, Sanchez R, Peters-Strickland T. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015 Feb;18(2):145-54. doi: 10.3111/13696998.2014.979936. Epub 2014 Nov 10. PubMed 25347448 ↗
  • Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013 Jul;16(7):917-25. doi: 10.3111/13696998.2013.804411. Epub 2013 May 28. PubMed 23663091 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2011
First posted
Sep 13, 2011
Start
Sep 2011
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Mar 27, 2015
Last update
May 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01432444
Responsible party
Sponsor
First posted
Sep 13, 2011
Start date
Sep 2011
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Mar 27, 2015
Last update
May 7, 2015

Study contacts

Kevin Cox, MD
study director · Kevin.TC-Cox@otsuka-us.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion